JP7821271B2 - 脂質ナノエマルション粒子に吸着したｍＲＮＡの凍結乾燥製剤 - Google Patents

脂質ナノエマルション粒子に吸着したｍＲＮＡの凍結乾燥製剤

Info

Publication number
JP7821271B2
JP7821271B2 JP2024512095A JP2024512095A JP7821271B2 JP 7821271 B2 JP7821271 B2 JP 7821271B2 JP 2024512095 A JP2024512095 A JP 2024512095A JP 2024512095 A JP2024512095 A JP 2024512095A JP 7821271 B2 JP7821271 B2 JP 7821271B2
Authority
JP
Japan
Prior art keywords
mrna
temperature
freeze
pressure
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024512095A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532292A (ja
Inventor
スワルネンドゥ カヴィラジ，
サンジェイ シン，
スニル ラウト，
パヴァン カルディル，
アジェイ シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gennova Biopharmaceuticals Ltd
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of JP2024532292A publication Critical patent/JP2024532292A/ja
Application granted granted Critical
Publication of JP7821271B2 publication Critical patent/JP7821271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024512095A 2021-08-25 2022-08-24 脂質ナノエマルション粒子に吸着したｍＲＮＡの凍結乾燥製剤 Active JP7821271B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121038492A IN202121038492A (https=) 2021-08-25 2021-08-25
IN202121038492 2021-08-25
PCT/IN2022/050753 WO2023026301A1 (en) 2021-08-25 2022-08-24 LYOPHILISED FORMULATIONS OF mRNA ADSORBED ONTO LIPID NANO-EMULSION PARTICLES

Publications (2)

Publication Number Publication Date
JP2024532292A JP2024532292A (ja) 2024-09-05
JP7821271B2 true JP7821271B2 (ja) 2026-02-26

Family

ID=85321644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512095A Active JP7821271B2 (ja) 2021-08-25 2022-08-24 脂質ナノエマルション粒子に吸着したｍＲＮＡの凍結乾燥製剤

Country Status (11)

Country Link
US (1) US20240350413A1 (https=)
EP (1) EP4392023A4 (https=)
JP (1) JP7821271B2 (https=)
KR (1) KR20240046787A (https=)
AU (1) AU2022335015B2 (https=)
CA (1) CA3229958A1 (https=)
CL (1) CL2024000566A1 (https=)
CO (1) CO2024002142A2 (https=)
IN (1) IN202121038492A (https=)
WO (1) WO2023026301A1 (https=)
ZA (1) ZA202402153B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
WO2024261766A1 (en) * 2023-06-23 2024-12-26 Gennova Biopharmaceuticals Ltd. Lyophilised vaccine formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4026568A1 (en) * 2015-04-17 2022-07-13 CureVac Real Estate GmbH Lyophilization of rna
US20240350410A1 (en) * 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Anderson E. J. et al.，N Engl J Med，2020年，Vol. 383, No. 25，pp. 2427-2438
Gerhardt et al.，bioRxiv，2021年02月02日，2021.02.02.429283，pp. 1-26
Polack F. P. et al.，N Engl J Med，2020年，Vol. 383, No. 27，pp. 2603-2615

Also Published As

Publication number Publication date
EP4392023A1 (en) 2024-07-03
ZA202402153B (en) 2024-10-30
IN202121038492A (https=) 2023-03-03
WO2023026301A1 (en) 2023-03-02
US20240350413A1 (en) 2024-10-24
JP2024532292A (ja) 2024-09-05
EP4392023A4 (en) 2025-07-09
KR20240046787A (ko) 2024-04-09
CO2024002142A2 (es) 2024-04-18
AU2022335015A1 (en) 2024-03-14
CL2024000566A1 (es) 2024-09-23
CA3229958A1 (en) 2023-03-02
AU2022335015B2 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
JP7821271B2 (ja) 脂質ナノエマルション粒子に吸着したｍＲＮＡの凍結乾燥製剤
KR101695800B1 (ko) 항원보강제 함유 백신 조성물의 안정화 방법
AU2007251604B2 (en) Nicotine-carrier vaccine formulation
AU765177B2 (en) Polynucleotide composition, method of preparation, and use thereof
CN116549626A (zh) 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用
CN114224851A (zh) 一种人白细胞介素10-Fc融合蛋白的冻干粉制剂及制备方法
EA050946B1 (ru) ЛИОФИЛИЗИРОВАННЫЕ ПРЕПАРАТЫ мРНК, АДСОРБИРОВАННОЙ НА ЛИПИДНЫХ ЧАСТИЦАХ НАНОЭМУЛЬСИИ
Zhen et al. Drying technologies for messenger RNA and other nucleic acid-lipid nanoparticles: Advances in freeze-drying and beyond
US20160051485A1 (en) Biodegradable Bionanoparticles for Releasing the GSE24-2 Peptide, Method for the Production Thereof, and Use of Same
CN115350281B (zh) 一种病毒样颗粒疫苗冻干保护剂及其制备方法
WO2024261766A1 (en) Lyophilised vaccine formulation
CN121154559A (zh) 一种载核酸脂质纳米颗粒的冻干制剂的制备方法
Pandya et al. Letters in Applied NanoBioScience
HK1229217A1 (en) Process for stabilizing an adjuvant containing vaccine composition
HK1229217A (en) Process for stabilizing an adjuvant containing vaccine composition
HK1229217B (zh) 一种使含佐剂的疫苗组合物稳定的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240417

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241002

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260213

R150 Certificate of patent or registration of utility model

Ref document number: 7821271

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150